Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homvioalbin
- Development stage
- Unknown
- Lead developer
- Homviora Arzneimittel Dr. Hagedorn
- Administration
- Oral
01
Overview
Homvioalbin is a homeopathic medicinal product developed by HOMVIORA Arzneimittel Dr. Hagedorn GmbH & Co. KG, specifically indicated for the management of mild hypertension. It is a monocomponent preparation containing a potentized extract of *Viscum album* (mistletoe), typically at a D1 dilution level. The drug was the subject of a Phase 2, prospective, randomized, 3-arm parallel clinical trial that compared its antihypertensive efficacy and sedative potential—measured via EEG theta power—against the complex homeopathic remedy Homviotensin and the beta-blocker metoprolol. The study concluded that Homvioalbin effectively lowers blood pressure without inducing the sedation or central nervous system depression often associated with conventional antihypertensive agents. It is currently marketed in Germany as a registered homeopathic pharmaceutical.
- Brand names
- Homvioalbin
- Other names
- Viscum album D1
Beyond the preview
Go deeper on Homvioalbin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Homvioalbin.